<DOC>
	<DOCNO>NCT02309827</DOCNO>
	<brief_summary>This study first human study PF-06651600 . PF-06651600 develop treatment inflammatory bowel disease . This study test single multiple dos PF-06651600 . The goal study assess safety , tolerability , pharmacokinetics pharmacodynamics PF-06651600 healthy volunteer .</brief_summary>
	<brief_title>Safety Pharmacokinetic Study PF-06651600 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male/female subject 18 55 year old , inclusive . Females must nonchild bear potential . BMI 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence personally sign date informed consent document . Willing able comply schedule visit , treatment plan , lab test study procedure . Subjects must avoid high intensity UV light exposure ( eg , active sunbathing , tan beds/booths sunlamp ) first dose study drug duration study . Evidence history clinically significant hematological , renal , endocrine , pulmonary , GI , cardiovascular , hepatic , psychiatric , neurologic , allergic disease . Use tobacco/nicotine containing product excess 5 cigarettes/day . History regular alcohol consumption exceed 14 drinks/week female 21 drinks/week male . Screening blood pressure &gt; 140/90 mm Hg . Screening laboratory abnormality define protocol . Unwilling unable comply Lifestyle Guidelines define protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Inflammatory bowel disease</keyword>
</DOC>